As the demand for app-based services grows, now may be the time to invest in UX research to identify needed improvements and enhancements.
Back to team page
Andrew Zawisza
Quality Director
Andrew has 10 years of experience in the medical device industry in various roles within quality assurance and regulatory affairs. During this time, he led preparation efforts for a successful first-time FDA inspection, research efforts to support 510(k) submissions, and investigation and resolution of product and process deficiencies. He also implemented statistical methods and lean tools to improve process efficiency. This experience has provided him with a unique perspective on how a quality system can be an effective tool for any company. At Bold Insight, Andrew is responsible for the development and maintenance of our quality system, ensuring the continuous improvement of our processes and the quality of service we provide our clients. Andrew holds an BS in Bioengineering from Michigan State University.
Bold facts
Learn more about
Something unique about you summed up in one sentence:
Your favorite part of working at Bold Insight:
In your spare time (or if you had spare time), you would absolutely do this:
How long have you been in the UX field?
Your favorite city in the world is...and why?
Your ultimate celebrity dinner party guest list would include:
Long-term personal or professional goal?
Any other facts to share?
Read our team’s latest bold insights
Human factors research in the times of COVID
Human factors research in the support of medical and drug delivery device commercialization is essential and we should be planning on a return to in-person research as soon as is possible by applying all available and practical protective measures.
COVID-19: Using human factors and UX to make a positive impact
We have aggregated some considerations for HCPs, healthcare organizations, and others involved in the medical space.
Is FMEA inadequate for human factors analyses?
A “traditional” risk assessment does not meet the needs of FDA-required human factors analyses.